Metacrine, Inc. (MTCR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 David M. Maggio.
MTCR 을(를) 보유 IPO 날짜 2020-09-16, 10 명의 정규직 직원, 에 상장 NASDAQ Capital Marke.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
